Bioelectronica Secures Series A Funding to Accelerate Drug Discovery and Development

VCBeat has learned that biotechnology company Bioelectronica Corporation (“Bioelectronica”) recently announced the completion of its Series A financing, co-led by its angel-round lead investor CoWin Ventures and this round’s lead investor Proxima Capital. The funds will be used to expand the team and drive new applications of the Hypercell® platform in cell line development and antibody discovery, thereby enabling iterative and rapid advancements in digital cell biology through innovative assay systems and scalable microfluidic chip technologies.

Jonathan Hull, Co-founder and CEO of Bioelectronica, stated, “We are delighted to partner with these investment firms as we continue to develop and launch our proprietary single-cell sorting platform, Hypercell®. This platform leverages computer vision, data science, and lensless imaging technologies to perform single-cell sorting assays with unprecedented total throughput. By embedding high-speed automation into its proprietary algorithm-driven, real-time analytical Computer Vision Single-Cell Sorting (CVSCS) system, Bioelectronica enables researchers to accelerate the early identification of positive B-cell clones during antibody discovery and development. With the deployment of Hypercell®, we have the potential to truly empower R&D teams to build their product pipelines and patent portfolios at an unprecedented pace by enhancing workflow efficiency.”

Huang Xin, Managing Partner at CoWin Ventures, stated, “Addressing the pain points researchers face in antibody discovery—particularly the lengthy workflows and risk of clone loss during clonal cell line screening—Bioelectronica has provided an ingenious and practical automated solution. Its capabilities in high-throughput processing, ease of operation, accurate sorting, and single-cell output have left a deep impression on us. We believe the Hypercell platform can accelerate the development of valuable therapeutic targets by researchers. As an early investor in Bioelectronica, CoWin Ventures remains deeply focused on the healthcare sector and continues to be optimistic about Bioelectronica’s future competitive advantages.”

Bioelectronica is a research-stage biotechnology company building intelligent digital tools for drug discovery, cell screening, and cell sorting. Bioelectronica’s platform technology combines computer vision, biochemical reagents, and consumer electronics to accelerate the pace of discovery. We believe that by transforming biochemistry through digital innovation, we will fundamentally change the speed and cost of therapeutic drug discovery and development.

CoWin Ventures is a China-US dual-currency venture capital firm focused on investing in early-stage technology companies, advocating a team culture of equality, transparency, sharing, and innovation. Established in 2009, the firm concentrates on the healthcare and IT hard-tech sectors. It has independently managed 17 funds with cumulative assets under management exceeding RMB 5 billion, providing financial and resource support to more than 100 outstanding teams and projects. CoWin Ventures has empowered numerous enterprises, including Taimei Medical Technology, Genetron Health, Huake Jingzhun, Thrive, and Cytek, enabling them to stand out in their respective niche markets. Additionally, it has facilitated the successful public listings of over ten high-tech companies, such as InnoLight Technology (300308), MEMSensing Microsystems (688286), Eastsoft (300183), Huaxing Zhiyuan (000008), Aolian Electronics (300585), and San Chao Advanced Materials (300554).

Proxima Capital, established in July 2016, focuses on the healthcare sector and serves exceptional medical technology innovators with significant growth potential. Leveraging an extensive network of industry partners and hospitals, Proxima Capital’s interdisciplinary team integrates market intelligence into its investment strategy, further driving the growth and success of its portfolio companies.